Why in News?
India has launched its first indigenous antibiotic, Nafithromycin. It is a significant milestone in the fight against antimicrobial resistance (AMR). This drug is designed to treat infections caused by drug-resistant bacteria, particularly community-acquired bacterial pneumonia (CABP), and aims to tackle the global health emergency of antimicrobial resistance.
Key Highlights of Nafithromycin Launch:
- First Indigenous Antibiotic: Developed in India, Nafithromycin is the first new antibiotic to be developed in over 30 years.
- Brand Name: Marketed under the brand name Miknaf.
- Launched by: Dr. Jitendra Singh, the Minister for Science and Technology, launched the drug in New Delhi.
- Collaboration: Developed with support from the Biotechnology Industry Research Assistance Council (BIRAC), a unit under the Department of Biotechnology (DBT).
- Target Disease: Specifically designed to treat community-acquired bacterial pneumonia (CABP) caused by drug-resistant bacteria like Streptococcus pneumonia.
- Global Impact: The launch comes at a critical time, as drug-resistant infections are rising globally, with an estimated 1 million deaths annually due to pneumonia.
Significance of Nafithromycin:
- Addressing AMR Crisis: AMR (Antimicrobial Resistance) is a silent pandemic, with estimates suggesting 1 million deaths annually from pneumonia alone. By 2050, it is projected that AMR could cause 10 million deaths annually worldwide.
- A Game Changer for Pneumonia: Pneumonia, a leading cause of death worldwide, is becoming increasingly difficult to treat due to drug-resistant bacteria. Nafithromycin is a critical tool in treating these resistant infections.
- Efficacy: Nafithromycin has been shown to be 10 times more effective than existing antibiotics, like Azithromycin, with a 3-day dosage regimen, making it highly efficient and appealing to doctors and patients.
|
Antibiotics and Their Role in Healthcare:
What is Pneumonia and Its Impact?
|
Why is Nafithromycin Important?
- Global Health Emergency: AMR has reached crisis levels globally, and the development of new antibiotics has stalled since the 1980s. Nafithromycin is the first new antibiotic developed in India in the last 30 years.
- Need for New Antibiotics: Existing antibiotics have become ineffective against superbugs. Nafithromycin can treat infections caused by bacteria that are resistant to current antibiotics.
- Safety and Tolerability: The drug has shown minimal side effects and is well-tolerated by patients, making it a safer option for a wider population, including those with comorbid conditions.
Role of Public and Private Partnerships:
- Public-Private Collaboration: The development of Nafithromycin demonstrates the power of collaboration between the public and private sectors.
- BIRAC’s Contribution: BIRAC played a crucial role in supporting clinical trials, investing 8 crore INR in the third phase. This is part of a broader effort to strengthen India’s bio-economy.
India’s Growing Biotech Sector:
- Bio-Economy Expansion: India’s biotechnology industry has grown significantly, from $10 billion in 2010 to $151 billion in 2023, with a projected goal of reaching $300 billion by 2030.
- Boost to Startups: The biotech startup ecosystem in India is flourishing, with over 8,000 startups in 2023. The support from organizations like BIRAC is helping accelerate the development of new medicines and technologies.
Nafithromycin has the potential to impact global healthcare, especially in developing countries like India, where the burden of pneumonia is significant. It serves as a beacon of hope in the battle against superbugs. With Nafithromycin, India takes a significant step forward in the global fight against antimicrobial resistance.
Explore our Books: https://apnipathshala.com/product-category/books/
Explore Our test Series: https://tests.apnipathshala.com/
